August 18th, 2010
•For development of RNA interference (RNAi)-based therapies, a novel strategy was developed, transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells. Here, tkRNAi was successfully applied for reversal of classical ABCB1-mediated multidrug resistance (MDR) of cancer cells.
Related Videos
Protocol for RNAi Assays in Adult Mosquitoes (A. gambiae)
Localized RNAi and Ectopic Gene Expression in the Medicinal Leech
Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast
MISSION esiRNA for RNAi Screening in Mammalian Cells
RNAi Interference by dsRNA Injection into Drosophila Embryos
RNAi Mediated Gene Knockdown and Transgenesis by Microinjection in the Necromenic Nematode Pristionchus pacificus
RNAi Screening to Identify Postembryonic Phenotypes in C. elegans
Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans
RNAi-mediated Gene Knockdown and In Vivo Diuresis Assay in Adult Female Aedes aegypti Mosquitoes
Phosphopeptide Analysis of Rodent Epididymal Spermatozoa
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved